Surfactant use for neonatal lung injury: Beyond respiratory distress syndrome

Paediatric Respiratory Reviews

Volumn 5, Issue SUPPL. A, 2004, Pages

  Finer, Neil N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CHOLESTEROL; CYTOKINE; DNA; FATTY ACID; HEMOGLOBIN; LIPID; LUNG SURFACTANT; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PLASMA PROTEIN; PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; ARTIFICIAL LUNG SURFACTANT;

ANTIBACTERIAL ACTIVITY; ATELECTASIS; BACTERIAL GROWTH; CHEMICAL COMPOSITION; CLINICAL TRIAL; DIAPHRAGM HERNIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EDEMA; ERYTHROCYTE; EXUDATE; GAS EXCHANGE; HIGH FREQUENCY VENTILATION; HISTOPATHOLOGY; HUMAN; LAMELLAR BODY; LEUKOCYTE MIGRATION; LUNG ALVEOLUS CELL TYPE 2; LUNG EDEMA; LUNG FUNCTION; LUNG HEMORRHAGE; LUNG HYPOPLASIA; LUNG INJURY; LUNG LAVAGE; LUNG MECHANICS; MECONIUM ASPIRATION; MORPHOLOGY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEUTROPHIL; NEWBORN MORTALITY; NONHUMAN; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW; SEPSIS; STREPTOCOCCUS AGALACTIAE; SUBSTITUTION THERAPY; SURFACE PROPERTY; TREATMENT OUTCOME; CLINICAL STUDY; CONGENITAL DIAPHRAGM HERNIA; DRUG INSTILLATION; DRUG MECHANISM; DRUG USE; FETUS LUNG MATURATION; HYALINE MEMBRANE DISEASE; LUNG EXTRAVASCULAR FLUID; LUNG GAS EXCHANGE; MECONIUM; NEUTROPHIL CHEMOTAXIS; NEWBORN; NEWBORN DISEASE; OUTCOMES RESEARCH; RESPIRATORY TRACT DISEASE;

EID: 1342312418     PISSN: 15260542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-0542(04)90053-X     Document Type: Review

References (81)

1. ElMetwally D, Vohr B, Tucker R. Survival and neonatal morbidity at the limits of viability in the mid 1990s: 22 to 25 weeks. J Pediatr 2000; 137(5): 616-622.
2. Soll RF. Synthetic surfactant treatment of RDS. In: Chalmers I, ed., Oxford Database of Perinatal Trials. Version 1.3, Disk Issue 8, Autumn 1992.
3. Soll RF. Natural surfactant extract vs synthetic surfactant in the treatment of established respiratory distress syndrome (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 1998.
4. Soll RF, Morley CJ. Prophylactic surfactant vs treatment with surfactant (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 1998.
5. Auten RL, Notter RH, Kendig JW, Davis JIM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101-107.
6. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92: 135-139.
7. Glick PL, Leach CL, Besner GE, et al. Pathophysiology of congenital diaphragmatic hernia III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 1992; 27: 866-869.
8. Lotze A, Whitsett JA, Kammerman LA, Ritter M, Taylor GA, Short BL. Surfactant protein A concentration in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation. J Pediatr 1990; 116: 435-440.
9. Bui KC, Walther FJ, Remedios DC. Phospholipid and surfactant protein concentrations in tracheal aspirates from infants requiring extracorporeal membrane oxygenation. J Pediatr 1992; 121: 271-274.
10. Lotze A, Knight GR, Martin GR, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993; 122: 261-268.
11. Ter Chen C, Toung TJK, Rogers MC. Effect of intra-alveolar meconium on pulmonary surface tension properties. Crit Care Med 1985; 13: 233-236.
12. Moses D, Holm BA, Spitale P, Liu M, Enhoming G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991; 164: 477-481.
13. Sun B, Herting E, Curstedt T, Robertson B. Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration. J Appl Physiol 1994; 77(4): 1961-1971.
14. Sun B, Curstedt T, Song GW, Robertson B. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate 1993; 63: 69-104.
15. Sun B, Curstedt T, Robertson B. Surfactant inhibition in experimental meconium aspiration syndrome. Acta Paediatr 1993; 82(22): 182.
16. Bae CW, Takahashi A, Chida S, Sasaki M. Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998; 44(2): 187-91.
17. Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A. Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997; 100(6): 998-1003.
18. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001; 50(1): 44-49.
19. Lam BCC, Yeung CY, Fu KH, Wong KY, Chan FL, Tsoi NS. Surfactant tracheobronchial lavage for the management of a rabbit model of meconium aspiration syndrome. Biol Neonate 2000; 78(2): 129-138.
20. Cochrane CG, Revak SD, Merritt TA, Schraufstatter IU, Hoch RC, Henderson C, Andersson S, Takamori H, Oades ZG. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res 1998; 44(5): 705-15.
21. Tierney DF, Johnson RP. Altered surface tension of lung extracts and lung mechanics. J Appl Physiol 1965; 20: 1253-1260.
22. Ikegami M, Jobe A, Berry D. A protein that inhibits surfactant in respiratory distress syndrome. Biol Neonate 1986; 50: 121-129.
23. Fuchimukai T, Fujiwara T, Takahashi A, Enhoming G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 1987; 62: 429-437
24. O'Brodovich HM, Weitz JI, Possmayer F. Effect of fibrinogen degradation products and lung ground substance on surfactant function. Biol Neonate 1990; 57: 325-333.
25. Kobayashi T, Nitta K, Ganzuka M, Inul S, Grossmann G, Robertson B. Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatr Res 1991; 29: 353-356.
26. Askin F. Respiratory tract disorders in the fetus and neonate. In: Wigglesworth JS, Singer DB, eds., Textbook of Fetal and Perinatal Pathology. 1989; Cambridge: Blackwell Scientific Publications, p. 674.
27. Baker CS, Evans TW, Randle BJ, Haslam PL. Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353(9160): 1232-1237.
28. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424-8429.
29. Seeger W, Grube C, Gunther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993; 6: 972-977.
30. Mbagwu N, Bruni R, Hernandez-Juviel JM, Waring AJ, Walther FJ. Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits. Mol Genet Metab 1999; 66(1): 40-8.
31. Herting E, Sun B, Jarstrand C, Curstedt T, Robertson B. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Childhood 1997; 76(1): F3-F8. Special issue.
32. Herting E, Gan XZ, Rauprich P, Jarstrand C, Robertson B. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Am J Respir Crit Care Med 1999; 159(6): 1862-1867.
33. Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX. Surfactant treatment in experimental Escherichia coli pneumonia. Acta Anaesthesiol Scand 1996; 40(9): 1154-1160.
34. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, Korfhagen TR. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165(7): 3934-3940.
35. Kennedy M, Phelps D, Ingenito E. Mechanisms of surfactant dysfunction in early acute lung injury. Exp Lung Res 1997; 23(3): 171-189.
36. Neumeister B, Woerndle S, Bartmann P. Effects of different surfactant preparations on bacterial growth in vitro. Biol Neonate 1996; 70(2): 128-134.
37. Rauprich P, Moller O, Walter G, Herting E, Robertson B. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clin Diagn Lab Immunol 2000; 7(5): 817-822.
38. Kitagawa M, Hislop A, Boyden EA, et al. Lung hypoplasia in congenital diaphragmatic hernia: A quantitative study of airway artery and alveolar development. Br J Surg 1971; 58: 342-346.
39. George DK, Cooney TP, Chiu BK, et al. Hypoplasia and immaturity of the terminal lung unit (acinus) in congenital diaphragmatic hernia. Am Rev Respir Dis 1987; 136: 947-950.
40. Glick PL, Stannard VA, Leach CL, Rossman J, Hosada Y, Morin FC, Cooney DR, Allen JE, Holm B. Pathophysiology of congenital diaphragmatic hernia II: The fetal lamb CDH model is surfactant deficient. J Pediatr Surg 1992; 27: 382-388.
41. Wilcox DT, Glick PL, Karamanoukian H, Rossman J, Morin FC, Holm BA. Pathophysiology of congenital diaphragmatic hernia. V. Effect of exogenous surfactant therapy on gas exchange and lung mechanics in the lamb congenital diaphragmatic hernia model. J Pediatr 1994; 124: 289-293.
42. O'Toole SJ, Karamanoukian HL, Morin FC, Holm BA, Egan EA, Azizkhan RG, Glick PL. Surfactant decreases pulmonary vascular resistance and increases pulmonary blood flow in the fetal lamb model of congenital diaphragmatic hernia. J Pediatr Surg 1996; 31(4): 507-11.
43. O'Toole SJ, Karamanoukian HL, Sharma A, Morin FC, Holm BA, Azizkhan RG, Glick PL. Surfactant rescue in the fetal lamb model of congenital diaphragmatic hernia. J Pediatr Surg 1996; 31(8): 1105-8; discussion 1108-9.
44. Suen HC, Catlin EA, Ryan DP, Wain JC, Donahoe PK. Biochemical immaturity of lungs in congenital diaphragmatic hernia. J Pediatr Surg 1993; 28: 471-477.
45. Scheffers EC, IJsselstijn H, Tenbrinck R, Lachmann B, de Jongste JC, Molenaar JC, Tibboel D. Evaluation of lung function changes before and after surfactant application during artificial ventilation in newborn rats with congenital diaphragmatic hernia. J Pediatr Surg 1994; 29(6): 820-4.
46. Crowley P, Chalmers I, Keirse MJNC. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1990; 97: 11-25.
47. Suen HC, Bloch KD, Donahoe PK. Antenatal glucocorticoid corrects pulmonary immaturity in experimentally induced congenital diaphragmatic hernia in rats. Pediatr Res 1994; 35: 523-529.
48. Losty PD, Pacheco BA, Manganaro TF, Donahoe PK, Jones RC, Schnitzer JJ. Prenatal hormonal therapy improves pulmonary morphology in rats with congenital diaphragmatic hernia. J Surg Res 1996; 65(1): 42-52.
49. Schnitzer JJ, Hedrick HL, Pacheco BA, Losty PD, Ryan DP, Doody DP, et al. Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep. Ann Surg 1996; 224(4): 430-7.
50. Tannuri U, Rodrigues CJ, Maksoud-Filho JG, Santos MM, Tannuri AC, Rodrigues Jr AJ. The effects of prenatal intraamniotic surfactant or dexamethasone administration on lung development are comparable to changes induced by tracheal ligation in an animal model of congenital diaphragmatic hernia: studies of lung glycogen content, elastic fiber density, and collagen content. J Pediatr Surg 1998; 33(12): 1776-83.
51. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101-107.
52. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92: 135-139.
53. Dragaville PA, South M, McDougall PN. Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr 2001; 138(1): 113-115.
54. Halliday HL, Speer CP, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Eur J Pediatr 1996; 155(12): 1047-1051.
55. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97(1): 48-52.
56. Lam BCC, Yeung CY. Surfactant lavage for meconium aspiration syndrome: A pilot study. Pediatrics 1999; 103(5): 1014-1018;
57. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane CG. A multicenter, randomized, controlled trial comparing surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002; 109(6): 1081-1087.
58. Lotze A, Knight GR, Martin GR, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993; 122: 261-268.
59. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 1998; 132(1): 40-7.
60. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336(9): 597-604.
61. Finer NN, Rhine WD, Verter J, for the Neonatal Inhaled Nitric Oxide Study (NINOS), Canadian Inhaled Nitric Oxide Study Group, NICHD Neonatal Research Network. Outcome predictors in near term infants with hypoxic respiratory failure. Evaluation of NINOS control infants. Pediatr Res 1998; 43: 214A.
62. Clyman RI, Jobe A, Heymann M, et al. Increased shunt through the patent ductus arteriosus after surfactant replacement therapy. J Pediatr 1982; 100: 101 -107.
63. Kaapa P, Seppanen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993; 123: 115-119.
64. Bloom MC, Roques-Gineste M, Fries F, Lelong-Tissier MC. Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome. Arch Dis Childhood 1995; 73: F95.
65. Hintz SR, Suttner DM, Sheehan AM, Rhine WD, VanMeurs KP. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): How new treatment modalities have affected ECMO utilization. Pediatrics 2000; 106(6): 1339-1343.
66. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160(4): 1188-95.
67. Herting E, Gefeller O, Land M, vanSonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106(5): 957-964.
68. Fetter WPF, Baerts W, Bos AP, Vanlingen RA. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995; 84(1): 14-16.
69. Harms K, Herting E. Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration 1994; 61(6): 348-352.
70. Berk C, Grundy M. High risk lecithin/sphingomyelin ratios associated with neonatal diaphragmatic hernia. Case Reports. Br J Obstet Gynecol 1982; 89: 250-251.
71. Moya FR, Thomas VL, Romaguera J, Mysore MR, Maberry M, Bernard A, Freund M. Fetal lung maturation in congenital diaphragmatic hernia. Am J Obstet Gynecol 1995; 173(5): 1401-5.
72. Sullivan KM, Hawgood S, Flake AW, Harrison MR, Adzick NS. Amniotic fluid phospholipid analysis in the fetus with congenital diaphragmatic hernia. J Pediatr Surg 1994; 29(8): 1020-3; discussion 1023-4.
73. Wigglesworth JS, Desai R, Guerrini P. Fetal lung hypoplasia: Biochemical and structural variations and their possible significance. Arch Dis Child 1981; 56: 606-615.
74. Bos AP, Tibboel D, Hazebroek FW, Molenaar JC, Lachmann B, Gommers D. Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 1991; 338(8777): 1279.
75. Glick PL, Leach CL, Besner GE, Egan EA, Morin FC, Malanowska-Kantoch A, Robinson LK, Brody A, Lele AS, McDonnell M, et al. Pathophysiology of congenital diaphragmatic hernia. III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 1992; 27(7): 866-9.
76. Lotze A, Knight GR, Anderson KD, Hull WM, Whitsett JA, O'Donnell RM, Martin G, Bulas DI, Short BL. Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 1994; 29(3): 407-12.
77. Somaschini M, Locatelli G, Salvoni L, Bellan C, Colombo A. Impact of new treatments for respiratory failure on outcome of infants with congenital diaphragmatic hernia. Eur J Pediatr 1999; 158(10): 780-4.
78. Dubois A, Storme L, Jaillard S, Truffert P, Riou Y, Rakza T, Pierrat V, Gottrand F, Pruvot FR, Leclerc F, Lequien P. Congenital hernia of the diaphragm. A retrospective study of 123 cases recorded in the Neonatal Medicine Department, URHC in Lille between 1985 and 1996]. Arch Pediatr 2000; 7(2): 132-42.
79. Vhitsett JA, Nogee LM, Weaver TE, Horowitz AD. Human surfactant protein B: Structure, function, regulation, and genetic disease. Physiol Rev 1995; 75(4): 749-757.
80. Tokieda K, Whitsett JA, Clark JC, Weaver TE, Ikeda K, McConnell KB, Jobe AH, Ikegami M, Iwamoto HS. Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol Lung Cell Mol Physiol 1997; 17(4): L875-L882.
81. Sleight E, Coombs RC, Gibson AT, Primhak RA. Neonatal respiratory distress in near-term infants-Consider surfactant protein B deficiency. Acta Paediatr 1997; 86(4): 428-430.